Health and population

Health and population dynamics are intertwined, embodying an intricate relationship with significant implications on the Sustainable Development Goals (SDGs). Health is fundamentally at the center of these 17 global goals, aimed to transform the world by 2030. Specifically, Goal 3 endeavors to "Ensure healthy lives and promote well-being for all at all ages." It acknowledges that health is pivotal to human life quality, social cohesion, and sustainable development. Inextricably linked to this are the complexities of population dynamics, including growth rates, age structure, fertility and mortality rates, and migration patterns.

With the world's population projected to exceed 9.7 billion by 2050, the pressure on health systems will undoubtedly escalate. The demographic transition, with an aging population and an increasing prevalence of non-communicable diseases, poses new challenges for health systems globally. Additionally, areas with high fertility rates often overlap with extreme poverty, resulting in heightened health risks, including higher maternal and child mortality rates, malnutrition, and infectious diseases.

Moreover, rapid urbanization and migration present both opportunities and threats to health. While urban areas may provide better access to healthcare, they also harbor risks of disease transmission, air and water pollution, and social determinants of health like inadequate housing and social inequality. Simultaneously, migrants often face disproportionate health risks due to unstable living conditions, exploitation, and limited access to healthcare services.

Achieving the SDGs will necessitate comprehensive approaches that consider the intricate interplay of health and population dynamics. It means strengthening health systems, promoting universal health coverage, and addressing social determinants of health. It also implies crafting policies that recognize demographic realities and foster an environment conducive to sustainable development. Only by understanding and harnessing these dynamics can the world meaningfully progress towards realizing the SDGs, ensuring healthy lives and well-being for all.

This article provides a comprehensive review of the use of graphene-based biosensing platforms for the early detection of Alzheimer's disease. It is found that graphene-based biosensors can detect Alzheimer's disease biomarkers at femtomolar concentrations, enabling early diagnosis before symptom onset. These sensors can also identify multiple biomarkers simultaneously in accessible biofluids like blood, saliva, and urine, enabling less invasive testing.
Report on a new smart delivery system designed to target and treat Alzheimer's disease more effectively, aiming to overcome the challenges of current treatments and offering a promising way to fight Alzheimer's more accurately and safely.

World Alzheimer's Day, observed every year on September 21st, is an international campaign to raise awareness and challenge the stigma surrounding Alzheimer's disease and other forms of dementia. With over 50 million people worldwide living with dementia and millions more being diagnosed every year, it is crucial to improve public understanding and provide support for those affected. In this article, we will discuss the significance of World Alzheimer's Day and share ways you can get involved to make a difference.

This study introduces a new, safe, affordable, and non-invasive device designed to detect and monitor early signs of Alzheimer's disease. Unlike traditional tests like MRI or CT scans, this device uses microwaves to examine the brain.
This article examines the associations between dietary inflammatory potential, antioxidant capacity, Mediterranean diet adherence, and biological age acceleration in a large UK Biobank cohort.
using neuroimaging, authors try to collect evidence associating polluting cooking fuels with cognitive function impairement in rural aging Indians.
The article estimates the value-based price of a blood test for Alzheimer's disease pathology, finding it would be $290-$1150 in primary care and $450-$1950 in specialty care, projecting substantial cost savings.
Elsevier,

Journal of Prevention of Alzheimer's Disease, Volume 12, 1 August 2025

The study found that long-duration and high-intensity walking were associated with reduced amyloid-beta accumulation over 4 years, with the greatest benefits seen in those who started walking earlier in life. However, walking activity was not linked to changes in tau deposition, neurodegeneration, or white matter hyperintensities.
This article describes the discovery and characterization of FJMU1887, a novel brain-penetrant small-molecule inhibitor of Galectin-3 (Gal-3) identified through an AI-driven drug discovery platform. FJMU1887 demonstrated potent anti-inflammatory effects, reduced Aβ pathology, and improved cognitive function in Alzheimer's disease mouse models, highlighting its therapeutic potential for the treatment of Alzheimer's disease.
Elsevier,

Journal of Pharmacology and Experimental Therapeutics, Volume 392, August 2025

This review discusses the dual role of amyloid-beta (Aβ) in Alzheimer's disease (AD). While Aβ accumulation is a hallmark of AD pathology, soluble Aβ also plays a neuroprotective role in regulating synaptic plasticity and memory. The review explores the potential of anti-Aβ immunotherapy as a treatment strategy, highlighting the need to balance targeting toxic Aβ species while preserving the physiological functions of Aβ.`

Pages